TSS
MCID: TXC005
MIFTS: 63

Toxic Shock Syndrome (TSS)

Categories: Infectious diseases

Aliases & Classifications for Toxic Shock Syndrome

MalaCards integrated aliases for Toxic Shock Syndrome:

Name: Toxic Shock Syndrome 12 75 55 15 72 33
Septic Shock 17 33
Staphylococcal Toxic Shock Syndrome 72
Shock, Septic 44
Toxic Shock 12
Tss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:14115
ICD9CM 35 040.82
MeSH 44 D012772
NCIt 50 C35498
SNOMED-CT 68 18504008
ICD10 33 A48.3 R57.2
UMLS 72 C0600327 C3714602

Summaries for Toxic Shock Syndrome

Disease Ontology : 12 A commensal bacterial infectious disease that results in infection, has material basis in Streptococcus pyogenes or has material basis in Staphylococcus aureus , which produce toxins that are absorbed systemically and produce the systemic manifestations. The infection has symptom fever, has symptom rash, has symptom hypotension, has symptom multiorgan failure, has symptom desquamation, has symptom vomiting, has symptom diarrhea, has symptom headache, and has symptom nonfocal neurologic abnormalities.

MalaCards based summary : Toxic Shock Syndrome, also known as septic shock, is related to staphylococcal toxic shock syndrome and streptococcal toxic-shock syndrome, and has symptoms including hypotension, fever and vomiting. An important gene associated with Toxic Shock Syndrome is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Simvastatin and Methylene blue have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 75 Toxic shock syndrome (TSS) is a condition caused by bacterial toxins. Symptoms may include fever, rash,... more...

Related Diseases for Toxic Shock Syndrome

Diseases related to Toxic Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 957)
# Related Disease Score Top Affiliating Genes
1 staphylococcal toxic shock syndrome 34.2 TNF IL1B IFNG HMGB1 CIITA
2 streptococcal toxic-shock syndrome 33.8 TNF MYOM2 LTA IL6 IL2 CXCL8
3 exanthem 32.0 TNF IL6 IL2
4 fasciitis 31.9 TNF IL6 CXCL8
5 pharyngitis 31.3 MYOM2 IL1B CXCL8
6 endometritis 31.1 TNF IL6 IL1B
7 vaginitis 31.1 IL6 IL1B CXCL8
8 acute pyelonephritis 31.0 IL6 IL10 CXCL8
9 necrotizing fasciitis 30.9 MYOM2 LTA IL6 IL2 CXCL8
10 adult respiratory distress syndrome 30.9 TNF IL6 IL10 CXCL8
11 chikungunya 30.9 TNF IL6 IL1B
12 kawasaki disease 30.9 TNF IL6 IL10
13 mastitis 30.8 TLR2 IL6 CXCL8
14 purpura 30.8 TNF SERPINC1 IL6
15 newborn respiratory distress syndrome 30.7 IL6 IL1B CXCL8
16 adult-onset still's disease 30.7 TNF IL6 IL1B
17 endomyocardial fibrosis 30.7 TNF IL4 IL10
18 dengue shock syndrome 30.7 TNF IL6 IL1B
19 reactive arthritis 30.6 TNF IL10 IFNG
20 infective endocarditis 30.6 TNF TLR2 IL6
21 laryngitis 30.6 TNF IL6 IL1B
22 psoriatic arthritis 30.5 TNF LTA IL6 IL1B
23 temporal arteritis 30.5 TNF IL6 IFNG
24 cytomegalovirus infection 30.5 TNF IL6 IL1B CXCL8
25 immune deficiency disease 30.5 IL4 IL2 IL10
26 shigellosis 30.5 LTA IL10 CXCL8
27 haemophilus influenzae 30.5 TNF TLR2 IL1B CXCL8
28 acute respiratory distress syndrome 30.5 TNF LTA IL6 IL1B CXCL8
29 juvenile rheumatoid arthritis 30.5 TNF LTA IL6 IL1B
30 intracranial hypertension 30.4 TNF SERPINC1 IL1B
31 capillary leak syndrome 30.4 IL6 IL2 CXCL8
32 synovitis 30.4 TNF IL6 IL1B CXCL8
33 erythema multiforme 30.4 TNF IL2 IFNG
34 rheumatic fever-related antigen 30.4 TLR2 MYOM2
35 herpes zoster 30.4 IL2 IL10 IFNG
36 bacterial pneumonia 30.3 TLR4 IL6 CXCL8
37 hematopoietic stem cell transplantation 30.3 TNF IL6 IL2 IL10 IFNG
38 scleritis 30.3 TNF IL4 IFNG
39 spondylitis 30.3 TNF LTA IL6
40 chronic graft versus host disease 30.3 TNF IL10 IFNG
41 mumps 30.3 TNF IL2 IFNG
42 sudden infant death syndrome 30.3 TNF IL6 IL1B IL10
43 pulmonary edema 30.3 TNF IL1B IL10 CXCL8
44 spotted fever 30.2 TNF IL10 IFNG
45 cystitis 30.2 TNF TLR4 IL6 CXCL8
46 cerebral palsy 30.2 TNF LTA IL6 IL1B
47 arteries, anomalies of 30.2 TNF SERPINC1 IL6 IL1B
48 proliferative glomerulonephritis 30.2 IL6 IL4 IFNG
49 pulmonary disease, chronic obstructive 30.2 TNF TLR2 IL6 CXCL8
50 cardiogenic shock 30.2 TNF IL6

Graphical network of the top 20 diseases related to Toxic Shock Syndrome:



Diseases related to Toxic Shock Syndrome

Symptoms & Phenotypes for Toxic Shock Syndrome

Symptoms:

12
  • hypotension
  • fever
  • vomiting
  • headache
  • diarrhea
  • rash
  • multiorgan failure
  • desquamation
  • nonfocal neurologic abnormalities

UMLS symptoms related to Toxic Shock Syndrome:


shock without mention of trauma

GenomeRNAi Phenotypes related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CXCL8 IL10 IL1B IL2 LTA TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CXCL8 IL10 IL1B IL2 LTA TNF

MGI Mouse Phenotypes related to Toxic Shock Syndrome:

46 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 CIITA EDNRA IFNG IL10 IL1B IL2
2 homeostasis/metabolism MP:0005376 10.37 CIITA EDNRA IFNG IL10 IL1B IL2
3 immune system MP:0005387 10.36 CIITA EDNRA IFNG IL10 IL1B IL2
4 cardiovascular system MP:0005385 10.32 EDNRA IFNG IL10 IL1B IL2 IL6
5 growth/size/body region MP:0005378 10.29 EDNRA IFNG IL10 IL1B IL2 IL4
6 endocrine/exocrine gland MP:0005379 10.26 CIITA EDNRA IFNG IL10 IL2 IL4
7 mortality/aging MP:0010768 10.23 EDNRA IFNG IL10 IL1B IL2 IL4
8 digestive/alimentary MP:0005381 10.22 EDNRA IFNG IL10 IL2 IL4 IL6
9 liver/biliary system MP:0005370 10.18 IFNG IL10 IL2 IL4 IL6 LTA
10 integument MP:0010771 10.15 EDNRA IFNG IL10 IL1B IL4 IL6
11 nervous system MP:0003631 10.11 EDNRA IFNG IL10 IL1B IL4 IL6
12 neoplasm MP:0002006 10.06 IFNG IL10 IL1B IL2 IL6 TLR2
13 muscle MP:0005369 9.98 EDNRA IFNG IL10 IL6 TLR2 TLR4
14 renal/urinary system MP:0005367 9.87 EDNRA IFNG IL4 IL6 SERPINC1 TLR2
15 reproductive system MP:0005389 9.86 IFNG IL10 IL2 IL4 IL6 SERPINC1
16 respiratory system MP:0005388 9.85 EDNRA IFNG IL10 IL2 IL4 IL6
17 skeleton MP:0005390 9.7 CIITA EDNRA IFNG IL10 IL1B IL4
18 vision/eye MP:0005391 9.32 EDNRA IFNG IL10 IL2 IL4 IL6

Drugs & Therapeutics for Toxic Shock Syndrome

Drugs for Toxic Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 450)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4 79902-63-9 54454
2
Methylene blue Approved, Investigational Phase 4 61-73-4
3
Oseltamivir Approved Phase 4 204255-11-8, 196618-13-0 65028
4
Enoximone Approved, Investigational Phase 4 77671-31-9 53708
5
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Polymyxin B Approved, Vet_approved Phase 4 1404-26-8
8
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
9
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
10
Zinc Approved, Investigational Phase 4 7440-66-6 32051
11
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
12
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
13
Adenosine Approved, Investigational Phase 4 58-61-7 60961
14
Amikacin Approved, Investigational, Vet_approved Phase 4 37517-28-5 37768
15
Vancomycin Approved Phase 4 1404-90-6 441141 14969
16
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
17
Dipyridamole Approved Phase 4 58-32-2 3108
18
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
19
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
20
Copper Approved, Investigational Phase 4 7440-50-8 27099
21
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
24
Pantoprazole Approved Phase 4 102625-70-7 4679
25
Metronidazole Approved Phase 4 443-48-1 4173
26
Lorazepam Approved Phase 4 846-49-1 3958
27
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
28
Etomidate Approved Phase 4 33125-97-2 36339 667484
29
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
30
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 64778 441130
31
Dobutamine Approved Phase 4 34368-04-2 36811
32
Propafenone Approved Phase 4 54063-53-5 4932
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
34
Succinylcholine Approved Phase 4 306-40-1 5314
35
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
36
Milrinone Approved Phase 4 78415-72-2 4197
37
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
38
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
39
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
40
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
41
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
42
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
43
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
44
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
45
Phenylephrine Approved Phase 4 59-42-7 6041
46
Ephedrine Approved Phase 4 299-42-3 9294
47
Pseudoephedrine Approved Phase 4 90-82-4 7028
48
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
49
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
50
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3

Interventional clinical trials:

(show top 50) (show all 953)
# Name Status NCT ID Phase Drugs
1 The Effect of Early Goal Directed Sedation on Microcirculation in Septic Shock Patients With Mechanical Ventilation Unknown status NCT02612363 Phase 4 Dexmedetomidine for sedation
2 The Effect of Dexmedetomidine on Microcirculation in Septic Shock- A Double-blinded Study Unknown status NCT02612181 Phase 4 Dexmedetomidine for dexmedetomidine group
3 Simvastatin in Patients With Septic Shock Unknown status NCT00450840 Phase 4 Simvastatin
4 COMPACT (COMbining Plasma-filtration and Adsorption Clinical Trial): Efficacy and Safety of High Doses CPFA (Coupled Plasma Filtration Adsorption) for Septic Shock in the ICU Unknown status NCT01639664 Phase 4
5 A Randomized Controlled Multi-Center Trial of the Early Application of CRRT in Patients With Severe Sepsis or Septic Shock Unknown status NCT00837057 Phase 4
6 A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China Unknown status NCT02647554 Phase 4 ulinastatin;Placebo
7 Potential Differences Between Levosimendan and Milrinone on Myocardial and Hemodynamic Variables in Patients With Septic Cardiomyopathy. Effects of Norepinephrine on Right Ventricular Function in Patient With Septic Shock. Unknown status NCT02640846 Phase 4 Norepinephrine;Milrinone;Levosimendan
8 Pharmacokinetics Variability of Ceftriaxone in Septic ICU Patients Unknown status NCT00449800 Phase 4 ceftriaxone
9 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
10 Microcirculation Guided Therapy Versus "Standard Treatment" of Severe Sepsis Unknown status NCT00484133 Phase 4 Dopamine;dobutamine;enoximone;nitroglycerine;noradrenaline
11 Methylene Blue and Ozone in Early Sepsis , a Randomized Double Blind Trial Unknown status NCT02910765 Phase 4 methylene blue;ozone
12 Importance of the Infusion Rate for the Plasma Expanding Effect of 5% Albumin in the Septic Patient Unknown status NCT03153306 Phase 4 albumin
13 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
14 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
15 Peripheral Perfusion Targeted Fluid Management in Critically Ill Patients: a Pilot Study Unknown status NCT01397474 Phase 4
16 Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study: a Multicenter, Prospective, Randomized Trial Comparing the State-of-the-Art Therapeutic Strategy Versus Early Surgery Strategy in Infective Endocarditis Unknown status NCT00624091 Phase 4
17 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
18 Continuous Administration of Norepinephrine Assisted by Fuzzy Logic Assisted Control in Septic Shock Patients Completed NCT00763906 Phase 4
19 An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock Completed NCT00279214 Phase 4 drotrecogin alfa (activated)
20 The Effect of Fluids and Norepinephrine for Mean Arterial Pressure Titration to Patients' Usual Levels on the Microcirculation of Initial Resuscitated Hypertensive Septic Shock Patients. Completed NCT02085291 Phase 4 Norepinephrine;Crystalloid
21 Dexmedetomidine Improve Microcirculatory Alterations in Initial Resuscitated Septic Shock Patients Completed NCT02270281 Phase 4 Dexmedetomidine 0.7 Mcg/kg/h
22 Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis Completed NCT02805049 Phase 4 Echinocandins
23 Multicenter, Prospective, Randomized, Controlled Open Study Albumin 20% Versus Saline Completed NCT00327704 Phase 4 albumin;saline
24 Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C Completed NCT02885168 Phase 4 Recombinant Activated Protein C;Phenylephrine
25 Population Pharmacokinetics and Pharmacodynamics Study of Piperacillin/Tazobactam During Early Phase in Critically Ill Patients With Severe Sepsis Completed NCT02730624 Phase 4 Piperacillin-tazobactam
26 Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue in Sepsis: A Randomized Controlled Trial Completed NCT03120637 Phase 4 Methylene Blue
27 Basel Study for Evaluation of Starch (130;0.4) Infusion in Septic Patients: BaSES (130;0.4) Trial Completed NCT00273728 Phase 4 hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline
28 Hemodynamic Assessment With Transpulmonary Thermodilution and Transesophageal Echocardiography in Patients With Early Septic Shock Completed NCT01188993 Phase 4
29 A Randomised Blinded Placebo Controlled Trial of Hydrocortisone in Critically Ill Patients With Septic Shock Completed NCT01448109 Phase 4 Hydrocortisone;Sterile air filled vial
30 Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension Completed NCT02519699 Phase 4 norepinephrine
31 Phase 4 Randomized Multicentric Controlled Study on Impact of Continuous Venovenous Hemofiltration on Organ Failure at the Early Phase of Severe Sepsis Completed NCT00406198 Phase 4
32 Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial Completed NCT02266264 Phase 4 Hydrocortisone
33 Double Blinded, Randomized Trial, Comparing Intravenous Bolus of 50 mg of Hydrocortisone Every 6 Hours for 7 Days With a Continuous Infusion of 300 mg Per Day of Hydrocortisone 300-mg Group During 5 Days in the Treatment of Septic Shock. Completed NCT02768740 Phase 4 Hydrocortisone hemisuccinate
34 Strategy of Early Improvement of Tissue Oxygenation Decrease the Mortality of Severe Sepsis Completed NCT01310790 Phase 4
35 Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units Completed NCT02213796 Phase 4 Meropenem
36 Dispositivo Adsorbente Con Polymyxina B Immobilizzata Nello Shock Settico - Studio Clinico Randomizzato e Prospettico, Multicentrico Completed NCT00629382 Phase 4
37 Investigating Nutritional Therapy With EPA, GLA and Antioxidants Role in Sepsis Treatment-INTERSEPT STUDY Completed NCT00329680 Phase 4
38 Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC) - a Randomised Clinical Trial Completed NCT02079402 Phase 4 Isotonic crystalloids
39 Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Amikacin in Patients With Severe Sepsis or Septic Shock Admitted at the Emergency Department(ED) Completed NCT02365272 Phase 4 Amikacin
40 Low-dose Hydrocortisone in the Treatment of the Shock of Burned Patients Completed NCT00149123 Phase 4 hydrocortisone 200 mg/day
41 The Effects of Different Vasopressors on the Innate Immune Response During Experimental Human Endotoxemia, a Pilot Proof-of-principle Study Completed NCT02675868 Phase 4 Norepinephrine;Phenylephrine;Vasopressins;Placebo
42 Adrenal Cortical Function and Vitamin A Deficiency in Sepsis, Severe Sepsis and Septic Shock: Prospective Randomized, Double Blind Placebo Controlled Clinical Trials Completed NCT03152474 Phase 4 Solumedrol 20mg;Vitamin A 100,000 IU
43 The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation Completed NCT01099566 Phase 4 Prasugrel;Placebo
44 The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia. Completed NCT01091571 Phase 4 Dipyridamole;Placebo
45 Influence of Sepsis, Age and SLCO1A2 Genetic Polymorphisms on Rocuronium Pharmacokinetics-pharmacodynamics in ASA I-III Surgical Patients Completed NCT02399397 Phase 4 General anesthesia
46 Efficacy and Toxicity of Aerosolised Colistin in Ventilator Associated Pneumonia: A Prospective, Randomized Trial Completed NCT02683603 Phase 4 AS colistin and "imipenem";IV colistin " and "imipenem" .;AS colimycin (colistin);IV colimycin (colistin);AS colistin and imipenem;IV colistin and imipenem
47 Effect of Antioxidants on Ocular Blood Flow, Endothelial Function, and Cytokine Levels in LPS Induced Inflammatory Model in Humans. Completed NCT00431691 Phase 4 vitamin and mineral supplement;Escherichia coli Endotoxin (LPS);100% O2;nitroglycerin
48 Randomized Directed Immuno Nutrition by L-arginine for Critically Ill Patients Completed NCT01038622 Phase 4 L-arginine;placebo
49 The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1 Completed NCT02384200 Phase 4 nitrofurantoin monohydrate/macrocrystalline capsules;ampicillin;gentamicin;vancomycin;ceftriaxone
50 A Comparative, Randomised Controlled Trial for Evaluating the Efficacy of Dexamethasone in the Treatment of Patients With Acute Respiratory Distress Syndrome Completed NCT01731795 Phase 4 Dexamethasone

Search NIH Clinical Center for Toxic Shock Syndrome

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Isoprenaline
Naloxone
Norepinephrine

Cochrane evidence based reviews: shock, septic

Genetic Tests for Toxic Shock Syndrome

Anatomical Context for Toxic Shock Syndrome

MalaCards organs/tissues related to Toxic Shock Syndrome:

41
Kidney, Liver, Lung, Neutrophil, Endothelial, Heart, T Cells

Publications for Toxic Shock Syndrome

Articles related to Toxic Shock Syndrome:

(show top 50) (show all 24096)
# Title Authors PMID Year
1
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. 9 38 71
10450718 1999
2
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. 71
16418737 2006
3
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 71
16865291 2006
4
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 71
14681301 2004
5
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. 71
14718719 2004
6
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 71
12746914 2003
7
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. 71
12485196 2002
8
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. 71
11826025 2002
9
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 71
11896460 2002
10
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. 71
11506397 2001
11
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 71
11261930 2001
12
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. 71
9818939 1998
13
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. 71
8056188 1994
14
Spectrum of sepsis, mediators, source control and management of bundles. 9 38
20515762 2010
15
Why not treat human cancer with interleukin-1 blockade? 9 38
20422276 2010
16
Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. 9 38
20421309 2010
17
Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. 9 38
20154607 2010
18
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. 9 38
20004006 2010
19
Sepsis, leukocytes, and nitric oxide (NO): an intricate affair. 9 38
19789465 2010
20
C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia. 9 38
19717486 2010
21
Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. 9 38
20119647 2010
22
The septic shock-associated IL-10 -1082 A > G polymorphism mediates allele-specific transcription via poly(ADP-Ribose) polymerase 1 in macrophages engulfing apoptotic cells. 9 38
20181890 2010
23
The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients. 9 38
20051843 2010
24
Augmentation of platelet and endothelial cell eNOS activity decreases sepsis-related neutrophil-endothelial cell interactions. 9 38
19536045 2010
25
The importance of determining procalcitonin and C reactive protein in different stages of sepsis. 9 38
20192933 2010
26
Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. 9 38
20472994 2010
27
Toll-like receptor 4 modulation as a strategy to treat sepsis. 9 38
20396414 2010
28
[Gene polymorphisms of Toll-like receptors in Chinese Han children with sepsis in Wenzhou]. 9 38
20441696 2010
29
A biomarker panel to discriminate between systemic inflammatory response syndrome and sepsis and sepsis severity. 9 38
20165718 2010
30
beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock. 9 38
19850944 2010
31
Early lactate clearance is associated with biomarkers of inflammation, coagulation, apoptosis, organ dysfunction and mortality in severe sepsis and septic shock. 9 38
20181046 2010
32
Immunogenicity of toxins during Staphylococcus aureus infection. 9 38
19947854 2010
33
Angiopoietin balance in septic shock patients treated by direct hemoperfusion with polymyxin b-immobilized fiber. 9 38
19954476 2009
34
Serum macrophage migration inhibitory factor reflects adrenal function in the hypothalamo-pituitary-adrenal axis of septic patients: an observational study. 9 38
20021698 2009
35
Evidence lost to treatment of critically-ill patients? 9 38
19940825 2009
36
Sick adrenal or sick euadrenal? 9 38
20001882 2009
37
Early suspension of activated protein C treatment in septic patients after shock reversal. 9 38
19474736 2009
38
Multicenter comparison of cortisol as measured by different methods in samples of patients with septic shock. 9 38
19760208 2009
39
Relation of heart rate variability to serum levels of C-reactive protein, interleukin 6, and 10 in patients with sepsis and septic shock. 9 38
19327330 2009
40
Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. 9 38
19450686 2009
41
Mannose-binding lectin is a critical factor in systemic complement activation during meningococcal septic shock. 9 38
19793001 2009
42
Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. 9 38
20146868 2009
43
C-reactive protein is not a useful indicator for infection in surgical intensive care units. 9 38
20512289 2009
44
The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. 9 38
19652948 2009
45
Urgent care in gynaecology: resuscitation and management of sepsis and acute blood loss. 9 38
19596611 2009
46
Regulation of triggering receptor expressed on myeloid cells 1 expression on mouse inflammatory monocytes. 9 38
19740375 2009
47
Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. 9 38
19551369 2009
48
Hemodynamic resuscitation in septic shock: cardiovascular support and adjunctive therapy. 9 38
19698279 2009
49
Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock of rats. 9 38
18848768 2009
50
Combined use of extracorporeal membrane oxygenation and activated protein C for severe acute respiratory distress syndrome and septic shock. 9 38
19577093 2009

Variations for Toxic Shock Syndrome

ClinVar genetic disease variations for Toxic Shock Syndrome:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 TNF TNF, -308G-A single nucleotide variant risk factor

Expression for Toxic Shock Syndrome

Search GEO for disease gene expression data for Toxic Shock Syndrome.

Pathways for Toxic Shock Syndrome

Pathways related to Toxic Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TREM1 TNF TLR4 TLR2 LTA IL6
2
Show member pathways
13.78 TNF TLR4 LTA IL6 IL4 IL2
3
Show member pathways
13.62 TNF LTA IL6 IL4 IL2 IL1B
4
Show member pathways
13.53 TNF TLR4 TLR2 LTA IL6 IL4
5
Show member pathways
13.47 TNF LTA IL6 IL4 IL2 IL1B
6
Show member pathways
13.4 TNF LTA IL6 IL4 IL2 IL1B
7
Show member pathways
13.34 TREM1 TNF TLR4 TLR2 IL4 IL2
8
Show member pathways
13.22 TREM1 TNF TLR4 TLR2 IL6 IL2
9
Show member pathways
13.06 TNF TLR4 TLR2 IL6 IL4 IL2
10
Show member pathways
13.03 TNF TLR4 TLR2 IL6 IL1B CXCL8
11
Show member pathways
13.01 TNF LTA IL6 IL4 IL2 IL1B
12 12.94